X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Small, mid caps underperform today 
(Wed, 25 Mar Closing) 
 
After opening the day on a positive note, the indices could not maintain their upward momentum through the day, thus closing well in the red. While the BSE-Sensex today closed lower by 50 points, the NSE-Nifty closed lower by 12 points. Smallcaps and midcaps too witnessed losses today. The BSE Mid Cap index and the BSE Small Cap index closed the day lower by 0.5% and 0.7% respectively. Sectoral indices closed the day on a mixed note.

As regards global markets, Asian indices closed on a mixed note today. The rupee was trading at Rs 62.34 to the dollar at the time of writing.

Pharma stocks have ended the day on a mixed note with Torrent Pharma and Wockhardt leading the gains. However, IPCA Labs and Elder Pharma lost considerable ground in today's trade. The stock of IPCA labs was down by over 12% in today's trade after the company received an US FDA import alert for two of its units located in Pithampur and Silvassa. In the past, IPCA's Indore and Ratlam units too had received a similar alert which led to a correction in stock price then. With respect to today's alert, there is some respite by the fact that two drugs from the Silvassa unit have been exempted which contributed about 70% to US sales in FY14. Had they been banned as well, IPCA's US sales would have come under pressure and the correction in stock price could have been even severe.

As per a leading business daily, pharma major Sun Pharma's management has expressed that its US$ 3.2 bn acquisition of Ranbaxy Laboratories is not going to restrict it from making further large acquisitions. Further, the company is looking to invest more than US$ 300 million in research and development. It is also not considering any job cuts post the closure of the Ranbaxy acquisition. The company's top management has also added that the company's biggest priority and focus going forward would be to win confidence of regulators.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Small, mid caps underperform today". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Jul 24, 2017 03:37 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS